Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/IGC Pharma, Inc./ 10-Q

Quarterly Report · 10-Q

IGC Pharma, Inc.

IGCNYSE_AMERICANEQUITYCurrent

Quarterly Report

Filed Aug 14, 2026Accepted Aug 14, 2026, 4:01 PM EDTCIK 1326205Accession 0001185185-26-003544
View company →Permanent SEC source ↗
Share

Company context

IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer’s dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With more than 30 patent filings, 12 patents granted and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.

Current securities

IGCNYSE_AMERICAN · EQUITY · Current
Historical securities (4)
IGCCOTC · EQUITY · Historical · closed Feb 26, 2019IGCIUOTC · UNIT · Historical · closed Mar 9, 2015IGCIWOTC · WARRANT · Historical · closed Mar 9, 2021IGC.WSNYSE_AMERICAN · WARRANT · Historical · closed Feb 25, 2016

Recent company filings

  1. DEFA14A filingOct 22, 2026
  2. DEF 14A filingOct 22, 2026
  3. 4 filingSep 29, 2026
  4. Regulation FD DisclosureJul 14, 2026
  5. Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesJul 6, 2026

Registered securities in this filing

IGC PHARMA, INC. · 10-Q · Filed 2026-08-14

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol
IGC
Exchange
NYSEAMER
Classification
COMMON
Status
Current
Filing context

Context: c0

Dimensions: Not supplied

Accession 000118518526003544 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.